GP Notification letter

VOmTEX Study: Randomised trial of volume of post-operative radiotherapy given to adult patients with extremity soft tissue sarcoma

Dear Dr.

Your patient has been diagnosed with extremity soft tissue sarcoma and has agreed to take part in the VORTEX clinical trial.

This is a prospective phase III multicentre randomised controlled clinical trial. The study is being coordinated by the Cancer Research UK Clinical Trials Unit (CRCTU) at the University of Birmingham.

The objective of the VORTEX trial is to assess if a reduced volume of post-operative radiotherapy increases limb function without compromising local control. An analysis of the association between dose, volumes irradiated and morbidity and functional outcome will be carried out.

A translational research study will be performed as part of the VORTEX trial. This study will involve collection of tumour and normal tissue samples at the time of surgery, which will be used for future microarray analyses. Also, blood samples will be taken prior to radiotherapy and these samples will be used for a future genetic study. Only those patients, who have consented to further research using their tumour and normal tissue samples and blood, will be entered for analysis in this study. Patients have the right to participate in the VORTEX trial without participating in the translational research.

Your patient has been provided with an information sheet for the trial (copy enclosed) which explains why s/he has been approached to take part in the trial, that the participation is entirely voluntary, and emphasises that they are free to withdraw from the trial at any time without prejudicing their future medical care.

Should you have any questions or require further information about this research, please do not hesitate to contact the nurse or doctor in charge of the local study.

Your contact: Tel:

You may also contact the VORTEX Study Office:

Tel: 0121 4143793 E-mail: VORTEX@trials.bham.ac.uk

Kind regards

Yours sincerely

Enc. VORTEX Patient Information Sheet

GP letter, Version 1, 16th January 2006